Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (1)	3/31/2001 11:24:55 AM
From: seminole	Read Replies (1) \| Respond to of 1840

Plenty of News....AACR with lots of abstracts. Prostate biz.yahoo.com

To: Spekulatius who wrote (1)	4/4/2001 11:48:38 PM
From: Miljenko Zuanic	Read Replies (3) \| Respond to of 1840

Spekulatious, You also do not have OSIP or IMCL in your portfolio. Why? EGF is one of the HOTEST new cancer target and both company (I do not believe to much in C225, but that is another story) deserve to be in portfolio. Also, ABGX (now in collaboration with IMNX) also have potent anti-EGFr antibody, now at the PI-end. Some other cancer targets will emerge in next 12 months, but I will leave them for that time. Miljenko